ES2563068T3 - Tratamiento de esclerosis múltiple (MS) con Campath-1H - Google Patents
Tratamiento de esclerosis múltiple (MS) con Campath-1H Download PDFInfo
- Publication number
- ES2563068T3 ES2563068T3 ES07802348.8T ES07802348T ES2563068T3 ES 2563068 T3 ES2563068 T3 ES 2563068T3 ES 07802348 T ES07802348 T ES 07802348T ES 2563068 T3 ES2563068 T3 ES 2563068T3
- Authority
- ES
- Spain
- Prior art keywords
- campath
- treatment cycle
- treatment
- multiple sclerosis
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Uso de Campath-1 H para la producción de un medicamento para reducir el riesgo de recidiva en un paciente que tiene una forma recidivante de esclerosis múltiple (MS) que ha recibido terapia previa para MS, en el que el tratamiento con Campath-1 H comprende un primer ciclo de tratamiento de Campath-1 H seguido de al menos un ciclo de tratamiento adicional de Campath-1 H, en el que cada ciclo de tratamiento comprende 1-5 dosis diarias que se aplican en días consecutivos, en el que la dosis diaria es >0 y <=12 mg, y en el que cada ciclo de tratamiento está separado del siguiente ciclo de tratamiento en al menos 1-24 meses, en el que dicho primer ciclo de tratamiento de Campath-1 H se administra a una dosis de 12 mg/día durante cinco días, y en el que dicho paciente se vuelve a tratar a los 12 meses después de dicho primer ciclo de tratamiento con un ciclo de tratamiento adicional de Campath-1 H a una dosis de 12 mg/día durante tres días
Description
Claims (1)
-
imagen1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84425106P | 2006-09-13 | 2006-09-13 | |
US844251P | 2006-09-13 | ||
EP06090169 | 2006-09-14 | ||
EP06090169 | 2006-09-14 | ||
PCT/EP2007/008084 WO2008031626A1 (en) | 2006-09-13 | 2007-09-11 | Treatment of multiple sclerosis (ms) with campath-1h |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2563068T3 true ES2563068T3 (es) | 2016-03-10 |
Family
ID=38734000
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES15191491T Active ES2917882T3 (es) | 2006-09-13 | 2007-09-11 | Tratamiento de esclerosis múltiple (MS) con Campath-1H |
ES07802348.8T Active ES2563068T3 (es) | 2006-09-13 | 2007-09-11 | Tratamiento de esclerosis múltiple (MS) con Campath-1H |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES15191491T Active ES2917882T3 (es) | 2006-09-13 | 2007-09-11 | Tratamiento de esclerosis múltiple (MS) con Campath-1H |
Country Status (22)
Country | Link |
---|---|
EP (4) | EP2433649A3 (es) |
JP (6) | JP5872756B2 (es) |
KR (2) | KR20150039879A (es) |
CN (1) | CN102652832A (es) |
AR (1) | AR062779A1 (es) |
BR (1) | BRPI0716929A8 (es) |
CA (1) | CA2662531A1 (es) |
CY (1) | CY2016019I2 (es) |
DK (1) | DK2066352T3 (es) |
ES (2) | ES2917882T3 (es) |
HK (1) | HK1136773A1 (es) |
HR (1) | HRP20160211T1 (es) |
HU (2) | HUE026740T2 (es) |
IL (3) | IL197236A (es) |
LT (1) | LTC2066352I2 (es) |
LU (1) | LU93092I2 (es) |
MX (2) | MX354080B (es) |
PL (2) | PL2066352T3 (es) |
PT (2) | PT2066352E (es) |
RS (1) | RS54658B1 (es) |
SI (1) | SI2066352T1 (es) |
WO (1) | WO2008031626A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008031626A1 (en) | 2006-09-13 | 2008-03-20 | Bayer Schering Pharma Aktiengesellschaft | Treatment of multiple sclerosis (ms) with campath-1h |
US9498528B2 (en) | 2006-09-13 | 2016-11-22 | Genzyme Corporation | Treatment of multiple sclerosis (MS) |
CN102459628A (zh) | 2009-05-13 | 2012-05-16 | 基酶有限公司 | 抗人cd52 免疫球蛋白 |
AR095199A1 (es) | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
TW201841653A (zh) * | 2017-04-21 | 2018-12-01 | 美商建新公司 | 以抗-cd52抗體治療多發性硬化症 |
US20220015500A1 (en) * | 2018-12-12 | 2022-01-20 | University Of Delaware | Vibrational device and methods for mitigating symptoms of freezing of gait |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5846534A (en) | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
WO2008031626A1 (en) | 2006-09-13 | 2008-03-20 | Bayer Schering Pharma Aktiengesellschaft | Treatment of multiple sclerosis (ms) with campath-1h |
-
2007
- 2007-09-11 WO PCT/EP2007/008084 patent/WO2008031626A1/en active Application Filing
- 2007-09-11 PL PL07802348T patent/PL2066352T3/pl unknown
- 2007-09-11 HU HUE07802348A patent/HUE026740T2/en unknown
- 2007-09-11 DK DK07802348.8T patent/DK2066352T3/en active
- 2007-09-11 MX MX2013009511A patent/MX354080B/es unknown
- 2007-09-11 EP EP11189431A patent/EP2433649A3/en not_active Withdrawn
- 2007-09-11 ES ES15191491T patent/ES2917882T3/es active Active
- 2007-09-11 PT PT78023488T patent/PT2066352E/pt unknown
- 2007-09-11 KR KR20157007655A patent/KR20150039879A/ko not_active Application Discontinuation
- 2007-09-11 ES ES07802348.8T patent/ES2563068T3/es active Active
- 2007-09-11 PT PT151914918T patent/PT3028718T/pt unknown
- 2007-09-11 EP EP15191491.8A patent/EP3028718B1/en active Active
- 2007-09-11 EP EP11189428A patent/EP2444104A3/en not_active Withdrawn
- 2007-09-11 RS RS20160081A patent/RS54658B1/en unknown
- 2007-09-11 KR KR1020097005111A patent/KR101583587B1/ko active IP Right Grant
- 2007-09-11 BR BRPI0716929A patent/BRPI0716929A8/pt active Search and Examination
- 2007-09-11 JP JP2009527751A patent/JP5872756B2/ja active Active
- 2007-09-11 CA CA002662531A patent/CA2662531A1/en not_active Abandoned
- 2007-09-11 CN CN2012100864372A patent/CN102652832A/zh active Pending
- 2007-09-11 MX MX2009002660A patent/MX2009002660A/es active IP Right Grant
- 2007-09-11 SI SI200731746A patent/SI2066352T1/sl unknown
- 2007-09-11 PL PL15191491.8T patent/PL3028718T3/pl unknown
- 2007-09-11 EP EP07802348.8A patent/EP2066352B1/en active Active
- 2007-09-13 AR ARP070104053A patent/AR062779A1/es not_active Application Discontinuation
-
2009
- 2009-02-25 IL IL197236A patent/IL197236A/en active IP Right Grant
-
2010
- 2010-02-26 HK HK10102029.9A patent/HK1136773A1/xx unknown
-
2013
- 2013-12-02 JP JP2013249139A patent/JP6257287B2/ja active Active
-
2015
- 2015-08-06 IL IL240394A patent/IL240394B/en active IP Right Grant
-
2016
- 2016-02-29 HR HRP20160211T patent/HRP20160211T1/hr unknown
- 2016-05-02 JP JP2016092377A patent/JP2016175929A/ja active Pending
- 2016-05-30 HU HUS1600028C patent/HUS1600028I1/hu unknown
- 2016-05-30 LT LTPA2016019C patent/LTC2066352I2/lt unknown
- 2016-05-31 CY CY2016019C patent/CY2016019I2/el unknown
- 2016-05-31 LU LU93092C patent/LU93092I2/de unknown
-
2017
- 2017-08-01 JP JP2017149006A patent/JP2018024655A/ja active Pending
-
2018
- 2018-02-04 IL IL257341A patent/IL257341A/en unknown
-
2019
- 2019-06-19 JP JP2019113260A patent/JP2019167385A/ja active Pending
-
2021
- 2021-04-14 JP JP2021068079A patent/JP2021107423A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2563068T3 (es) | Tratamiento de esclerosis múltiple (MS) con Campath-1H | |
ES2510565T3 (es) | Envase de ajuste de dosis para neramexano y su uso en el tratamiento de un trastorno del oído interno | |
ES2497494T3 (es) | Método de tratamiento y prevención del hiperparatiroidismo secundario | |
PE20160195A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
AR059390A1 (es) | Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos | |
CL2021001810A1 (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
CL2008002207A1 (es) | Composicion farmaceutica que comprende inmunosupresores para la mejora del efecto en el uso de un antagonista de interleucina-6 (il-6) para el tratamiento de enfermedades relacionadas con il-6 (div. sol. 896-04). | |
ECSP099178A (es) | Método de tratamiento del ictus con un trombolítico | |
UY27789A1 (es) | Metodos y modalidades de dosificación para la liberación controlada de oxicodona. | |
AR045972A1 (es) | Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas | |
ECSP109934A (es) | Compuesto - 946 | |
AR061122A1 (es) | Regimen de cladribina para tratar la escleorosis multiple | |
CO6280475A2 (es) | Metodo para tratar la deficiencia de vitamina b12 | |
CL2008001297A1 (es) | N-[(1s)-1-(5-fluoropirim idin-2-i1 )etil]-3-(5-isopropoxi-1 h-pirazol-3-il )-3h-imidazo[4,5-b]piridin-5amina o una sal farmacéuticamente aceptabie del mismo; composición farmacéutica que lo comprende; y su uso en el tratamiento del cáncer. | |
AR095338A1 (es) | Método de tratamiento no tóxico para la abstinencia de drogas | |
PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
AR095159A2 (es) | Una composición farmacéutica en forma de cápsula para administración oral | |
AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
CO5700723A2 (es) | Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca | |
AR115913A1 (es) | Formas de dosificación oral biodisponibles, uso, métodos | |
AR079000A1 (es) | Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas | |
CL2004000984A1 (es) | Forma de dosificacion oral de una sal de magnesio de (s)-pantopazol, para la profilaxis o tratamiento de una condicion asociada a inhibir la bomba protonica. | |
AR029666A1 (es) | Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina | |
CL2023000764A1 (es) | Formas farmacéuticas multipartículas que comprenden deutetrabenazina | |
UY28457A1 (es) | Nueva composición |